Collaboration
Piramal Pharma Solutions Announces Collaboration with BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment
Piramal Pharma Solutions
PR-M12-19-NI-005Dec 05, 2019
Clinical Trials
BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC
BerGenBio ASA
PR-M01-18-NI-035Jan 12, 2018
Oncology
Emphasis on Aggressive Cancer Cells
Richard Godfrey
BerGenBio ASA
PTV-M06-17-BIO-009Aug 16, 2017